Floatz logo

Humax-Cd20

Recurrent Burkitt Lymphoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Recurrent Burkitt Lymphoma cohort.

Asset / SponsorPhaseRating
Clofarabine
M.D. Anderson Cancer Center
Phase 2BB
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Blinatumomab
National Cancer Institute (NCI)
Phase 1/2B
MERCAPTOPURINE ANHYDROUS
M.D. Anderson Cancer Center
Phase 1/2CCC
Lentivirus Vector CCR5 shRNA
AIDS Malignancy Consortium
Phase 1/2CCC

Same molecule, other indications

Humax-Cd20 is also rated in:

B-cell chronic lymphocytic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
74 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →